Kura Oncology, Inc. — Q3 2023 Form 10-Q Summary
Business context and reporting period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision cancer medicines and molecularly targeted therapies. Its clinical pipeline comprises ziftomenib, tipifarnib and KO-2806, with no approved products and no product-sale revenue. This report covers the three and nine months ended September 30, 2023; financial statements are unaudited and presented under U.S. GAAP.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $29.3 million | $25.0 million | $82.7 million | $70.1 million |
| General and administrative expense | $13.1 million | $11.6 million | $36.3 million | $34.6 million |
| Total operating expenses | $42.5 million | $36.6 million | $119.0 million | $104.7 million |
| Other income, net | $3.9 million | $1.1 million | $9.2 million | $2.0 million |
| Net loss | $38.6 million | $35.5 million | $109.8 million | $102.7 million |
| Net loss per share | $0.50 | $0.53 | $1.53 | $1.54 |
| Cash used in operating activities | Not provided for quarter | Not provided for quarter | $90.5 million | $83.5 million |
There is no meaningful revenue or profit margin because the company has no product sales. Operating expenses increased approximately 16% in the quarter and 14% year to date, while net loss increased approximately 9% and 7%, respectively. Higher interest income substantially offset the higher operating expenses. Share-based compensation was $7.1 million in Q3 and $20.9 million year to date.
- Cash and cash equivalents at September 30, 2023 were $28.7 million; short-term investments were $423.9 million, for total cash, cash equivalents and short-term investments of approximately $452.6 million.
- Total assets were $473.8 million and stockholders’ equity was $429.9 million.
- Outstanding long-term debt was $9.3 million, representing a $10.0 million term loan net of discounts and issuance costs. The term loan carried a 10.90% interest rate at September 30, 2023 and matures November 2, 2027.
- Operating lease liabilities totaled $8.1 million, following an amendment extending the Boston lease through July 2031.
- The company reported an accumulated deficit of $678.7 million and has incurred operating losses and negative operating cash flow since inception.
Material changes versus the prior comparable period
- Research and development expense increased $4.4 million in Q3 and $12.6 million for the first nine months, primarily due to higher ziftomenib, KO-2806, discovery and personnel costs. Tipifarnib costs declined following closure of its registration-directed trial.
- General and administrative expense increased $1.5 million in Q3 and $1.8 million year to date.
- Interest and other income increased by $3.2 million in Q3 and $8.4 million year to date, primarily because of higher interest income on investments.
- Operating cash use increased $7.0 million year to date to $90.5 million. Investing cash flow changed from $79.9 million provided in 2022 to $26.6 million used in 2023, reflecting purchases of marketable securities.
- Financing cash flow increased to $94.1 million, primarily from the June 2023 public offering. Kura issued 5.66 million common shares and pre-funded warrants for 3.03 million shares, generating approximately $93.6 million of net proceeds.
- Common shares issued and outstanding increased from 68.3 million at December 31, 2022 to 74.3 million at September 30, 2023, excluding additional dilution from options, restricted stock units and warrants.
Guidance, outlook, commentary and risks
- Management expects existing cash, cash equivalents and short-term investments to fund operating expenses to mid-2026 based on current plans. This is not a guarantee and depends on clinical timelines, costs, regulatory outcomes and financing conditions.
- The Phase 2 registration-directed KOMET-001 study of ziftomenib in relapsed or refractory NPM1-mutant AML is expected to complete enrollment of 85 patients by mid-2024. Preliminary data from 20 patients in KOMET-007 are expected early in Q1 2024; KOMET-008 and a post-transplant maintenance program are expected to begin dosing in Q1 2024.
- KO-2806’s FIT-001 monotherapy study began dosing in October 2023, with combination dose-escalation cohorts in KRAS G12C-mutant NSCLC and clear-cell renal cell carcinoma expected by mid-2024.
- On November 2, 2023, after the reporting period, Kura entered a new $150.0 million at-the-market facility and terminated its prior facility, under which no shares had been sold.
- Kura may borrow up to $35.0 million under an available term-loan tranche through March 15, 2024, subject to the loan agreement. Additional tranches are subject to conditions and, for the final $25.0 million tranche, lender approval.
- Key risks include clinical-trial failure or delay, safety events, regulatory non-approval, patient enrollment and companion-diagnostic challenges, dependence on third-party manufacturers and collaborators, need for substantial additional capital, dilution, debt covenants and interest-rate exposure.
- The filing identifies no material legal proceedings and states that disclosure controls and procedures were effective as of September 30, 2023.
Important facts for investors to verify
- Whether ziftomenib’s Phase 2 enrollment and regulatory pathway remain on schedule, including the impact of differentiation syndrome and competing menin inhibitors.
- Actual quarterly cash burn and whether the stated mid-2026 cash runway changes as clinical programs expand.
- Future use of the $150.0 million ATM facility, potential equity dilution and availability of additional debt tranches.
- Clinical data and safety updates for ziftomenib, tipifarnib and KO-2806, including combination-trial results and companion-diagnostic progress.
- Debt covenant compliance, collateral provisions and the potential end-of-term fee under the Hercules term-loan facility.
- The filing’s disclosed pre-funded warrants, options, restricted stock units and performance-based awards, which may increase fully diluted shares outstanding.